Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
The purpose of this study is to determine if taking Vyvanse with Prilosec OTC or Adderall XR
with Prilosec OTC changes how quickly the drug is absorbed into the body and/or changes how
much of the drug is absorbed into the body.
A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)
The primary objective of this study is to assess the time of onset of Vyvanse compared to
placebo, in the analog classroom as measured by the Swanson, Kotkin, Agler, M. Flynn and
Pelham (SKAMP) deportment scale in children (aged 6-12) diagnosed with
Attention-Deficit/Hyperactivity Disorder (ADHD).
Pilot Study of Vyvanse™ In ADHD Adolescents at Risk for Substance Abuse
New York State Psychiatric Institute
This is an open label pilot study to obtain information on the best way to study young
adolescents with Attention Deficit Hyperactivity Disorder (ADHD)who may also be at risk of
developing substance abuse, in part because of their ADHD. The plan is to recruit older
children/young adolescents (age 11-15) who have ADHD and also have an older sibling with
substance abuse. The treatment for ADHD in the 11-15 year old will be Vyvanse, a novel
preparation of dextroamphetamine in which the molecule is inactivated and only becomes
activated when it is digested. This preparation is felt to be safer from diversion while at
the same time providing treatment for the younger siblings in which a bad outcome has already
occurred in the family, namely the older sibling's substance abuse. As mentioned, this is an
open-label study, a feasibility study to see if we can use this approach to study and treat
high risk youth before they develop substance abuse.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.